An Update on Shingles Vaccination
Shingles (Herpes Zoster) is a painful viral condition caused by the reactivation of the varicella–zoster virus (VZV), the same virus that causes chickenpox. Even though shingles can occur at any age, it disproportionately affects older adults and immunocompromised individuals, with risks increasing significantly after age 50. The most debilitating complication of shingles is post‑herpetic neuralgia (PHN), which can cause persistent pain long after the rash resolves. Vaccination remains the most effective way to prevent shingles and its complications. With evolving vaccine recommendations and the introduction of newer, more effective vaccines, it is imperative for healthcare professionals to stay updated on best practices for shingles immunization. This course provides the latest evidence‑based information on shingles vaccines, indications, schedules, contraindications, and implementation strategies for routine clinical practice.
.jpg)
Learning Outcomes
What you'll learn
- Describe the epidemiology and clinical impact of shingles and its complications.
- Identify the shingles vaccines currently approved and recommended, including their efficacy and safety profiles.
- Understand current vaccination schedules, age groups, and contraindications.
- Differentiate between live attenuated and recombinant shingles vaccines.
- Implement evidence‑based strategies to improve vaccine uptake among eligible populations.
- Address patient concerns, contraindications, and special scenarios for shingles vaccination.
Stay updated with our


Learning Outcomes
What you'll learn
- Describe the epidemiology and clinical impact of shingles and its complications.
- Identify the shingles vaccines currently approved and recommended, including their efficacy and safety profiles.
- Understand current vaccination schedules, age groups, and contraindications.
- Differentiate between live attenuated and recombinant shingles vaccines.
- Implement evidence‑based strategies to improve vaccine uptake among eligible populations.
- Address patient concerns, contraindications, and special scenarios for shingles vaccination.
Stay updated with our


Training Overview
- Epidemiology and Clinical Burden of Shingles
- Shingles Vaccines — Types, Mechanisms and Evidence
- Vaccination Recommendations and Schedules
- Safety, Contraindications and Special Populations
- Enhancing Vaccine Uptake and Overcoming Barriers
- Clinical Implementation, Documentation and Follow‑Up
- Summary
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
Top reviews
No reviews yet.
You May Also Like
Are you a qualified
Trainer or Instructor?
Join Care Learning as a trainer and deliver high-quality courses to learners across healthcare and workplace training.
Refer a Friend &
Earn Rewards.
Invite healthcare professionals to join Care Learning and get rewarded when your referral successfully joins.
Frequently asked questions
Shingles is a painful rash caused by reactivation of the varicella–zoster virus, typically years after initial chickenpox infection.
Adults aged 50 years and older are generally recommended for shingles vaccination, including those with stable chronic conditions.
The recombinant shingles vaccine is administered as a two‑dose series, typically spaced 2–6 months apart.
Yes — most side effects are mild and include injection site reactions, fatigue, and muscle pain. Serious adverse events are rare.
Yes — the recombinant vaccine can be administered concurrently with other age‑appropriate vaccines such as influenza and pneumococcal vaccines.
Contraindications include severe allergic reactions to vaccine components and certain immunocompromised conditions for live attenuated vaccines.
.jpg)
.jpg)
.jpg)



